Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2020

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2020

Summary

In 2019, the global Benign Prostatic Hyperplasia (BPH) Drugs market size was increased to US$ 3321.82 million from US$ 5014.51 million in 2015, and it will reach US$ 3482.83 million in 2026, growing at CAGR of 0.93% between 2020 and 2026.

This report focuses on Benign Prostatic Hyperplasia (BPH) Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Benign Prostatic Hyperplasia (BPH) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, APAC, South America and MEA.

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt and will significantly affect the Benign Prostatic Hyperplasia (BPH) Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Benign Prostatic Hyperplasia (BPH) Drugs industry.

By Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck

Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others

Segment by Application
Hospitals
Drugstores
Others

By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
South America
Brazil
Colombia
Argentina
Middle East & Africa
Middle East
Africa


1 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET OVERVIEW
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Comparison by Type (2020-2026)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application (2020-2026)
1.3.2 Hospitals
1.3.3 Drugstores
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2015-2026
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2015-2026
1.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2020 Versus 2026
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION BY MANUFACTURERS
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2020)
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2020)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2019-2020)
2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Headquarters, Established Date and Products Types
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
2.5.2 The Global 3 and 5 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.3.5 Mexico
3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Southeast Asia
3.5.9 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.5.10 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.5.11 Brazil
3.5.12 Colombia
3.5.13 Argentina
3.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.6.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.6.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.6.3 Middle East
3.6.4 Africa
4 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS HISTORIC MARKET ANALYSIS BY TYPE
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2015-2020)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2015-2020)
5 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS HISTORIC MARKET ANALYSIS BY APPLICATION
6 ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS INDUSTRY KEY MANUFACTURERS
6.1 Eli Lilly
6.1.1 Company Profile
6.1.2 Product Information
6.1.3 Sales, Price, Revenue and Gross Margin
6.2 GlaxoSmithKline
6.2.1 Company Profile
6.2.2 Product Information
6.2.3 Sales, Price, Revenue and Gross Margin
6.3 Astellas Pharma
6.3.1 Company Profile
6.3.2 Product Information
6.3.3 Sales, Price, Revenue and Gross Margin
6.4 Sanofi
6.4.1 Company Profile
6.4.2 Product Information
6.4.3 Sales, Price, Revenue and Gross Margin
6.5 Pfizer
6.5.1 Company Profile
6.5.2 Product Information
6.5.3 Sales, Price, Revenue and Gross Margin
6.6 Abbott
6.6.1 Company Profile
6.6.2 Product Information
6.6.3 Sales, Price, Revenue and Gross Margin
6.7 Allergan
6.7.1 Company Profile
6.7.2 Product Information
6.7.3 Sales, Price, Revenue and Gross Margin
6.8 TEVA
6.8.1 Company Profile
6.8.2 Product Information
6.8.3 Sales, Price, Revenue and Gross Margin
6.9 Mylan
6.9.1 Company Profile
6.9.2 Product Information
6.9.3 Sales, Price, Revenue and Gross Margin
6.10 Novartis
6.10.1 Company Profile
6.10.2 Product Information
6.10.3 Sales, Price, Revenue and Gross Margin
6.11 Merck
6.11.1 Company Profile
6.11.2 Product Information
6.11.3 Sales, Price, Revenue and Gross Margin
7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MANUFACTURING COST ANALYSIS
7.1 R&D Cost Analysis
7.1.1 Clinical Phase Costs
7.1.2 Capitalized Costs
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
7.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
8 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS
8.1 Marketing Channel
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
8.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
9 MARKET DYNAMICS
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 GLOBAL MARKET FORECAST 118
10.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2021-2026)
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Application
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2021-2026)
10.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.7 South America Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
11 RESEARCH FINDINGS AND CONCLUSION 127
12 METHODOLOGY AND DATA SOURCE 128
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables and Figures
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) & (US$ Million) Growth Rate Comparison by Type (2020-2026)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Comparison by Application (2020-2026)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (M Units) & (US$ Million): 2020 VS 2026
Table 4. Overview of the World Economic Outlook Projections
Table 5. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 6. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 8. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 9. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 10. Covid-19 Impact: Global Major Government Policy
Table 11. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Covered in This Study
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Manufacturers (2019-2020)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2020)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Manufacturers (2019-2020)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2019-2020)
Table 16. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2020)
Table 17. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Headquarters and Established Date
Table 18. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 19. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2019)
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2015-2020) (M Units)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2015-2020) (US$ Million)
Table 25. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)
Table 26. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 27. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 28. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 29. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)
Table 30. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 31. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 32. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 33. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2015-2020) (M Units)
Table 34. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)
Table 35. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2015-2020) (US$ Million)
Table 36. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)
Table 37. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)
Table 38. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 39. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 41. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)
Table 42. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)
Table 43. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 44. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Type (2015-2020)
Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2015-2020)
Table 49. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Unit) by Type (2015-2020)
Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook